Clinical study of amphotericin B in the treatment of invasive fungal infection in 111 hematological disorder patients with neutrocytopenia.
- Author:
Hong-yan TONG
1
;
Feng-juan ZHANG
;
Feng XIAO
;
Wen-bin QIAN
;
Hai-tao MENG
;
Wen-yuan MAI
;
Yin TONG
;
Li-ping MAO
;
Jie JIN
Author Information
- Publication Type:Journal Article
- MeSH: Agranulocytosis; complications; Amphotericin B; administration & dosage; therapeutic use; Antifungal Agents; administration & dosage; therapeutic use; Hematologic Diseases; complications; Humans; Liposomes; administration & dosage; therapeutic use; Mycoses; complications; drug therapy; Retrospective Studies; Treatment Outcome
- From: Chinese Journal of Hematology 2008;29(7):472-475
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the differences in clinical therapeutic effect and safety between amphotericin B and its liposome form in treating invasive fungal infection (IFI) in hematological disorder with neutrocytopenia.
METHODSOf 111 patients with IFI, 82 were treated with amphotericin B and 29 with amphotericin B liposome. The mean cumulative dose of amphotericin B was 617 (60-1895) mg and the mean course was 18 (7-60) d, and those for amphotericin B liposome was 925 (140-3420) mg and 13 (7-50) d, respectively.
RESULTSThe total effective rates of amphotericin B and its liposome groups were 69% and 58%, respectively (P>0.05). The adverse effect rates of chill and fever in amphotericin B and its liposome groups were 21% and 10% (P>0.05), hypopotassemia 34% and 14% (P=0.03), hepatic impairment 22% and 17% (P>0.05), and renal impairment 9% and 3%, respectively (P>0.05).
CONCLUSIONThe therapeutic effect for IFI of amphotericin B and its liposome was similar. The severe adverse reaction of amphotericin B liposome was slightly lower than that of amphotericin B.
